Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
Key Highlights
- ➤Lyell (LYEL) announces approximately $80 million private placement.
- ➤7,428,040 shares priced at $10.77 each, matching November 3 closing price.
- ➤Cash runway expected into 2028, including through ronde-cel’s anticipated BLA submission.
- ➤Ronde-cel pivotal data expected mid-2027; BLA submission planned for second half of 2027.
- ➤Additional PiNACLE trial data expected at ASH Annual Meeting in December 2026.
Expert Statements
Smital Shah, Chief Financial and Business Officer of Lyell Immunopharma
“This financing strengthens our financial position and supports the execution of our strategy as we approach several important clinical and regulatory milestones.”
Smital Shah, Chief Financial and Business Officer of Lyell Immunopharma
“We see a significant clinical and commercial opportunity for ronde-cel, which has the potential to deliver durable responses with a one-time treatment that can be administered in the outpatient setting.”
Smital Shah, Chief Financial and Business Officer of Lyell Immunopharma
“We are pleased to have the strong support of our syndicate of high-quality existing and new investors as we advance toward these important milestones.”
* Investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors. * Ronde-cel, a next-generation CD19/CD20 CAR T-cell product candidate, is advancing toward pivotal data in mid-2027, with the potential to deliver meaningful and durable clinical benefit for patients with relapsed/refractory large B-cell lymphoma * Proceeds expected to extend cash runway into 2028, beyond anticipated BLA submission for ronde-cel in the second half of 2027, as well as updated clinical data from our GCC-targeted LYL273 program for patients with metastatic colorectal cancer SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock. The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors.
Get started
Create a free account to read the full story.